Galmed Pharmaceuticals Ltd. (GLMD)

NASDAQ: GLMD · IEX Real-Time Price · USD
0.314
-0.002 (-0.73%)
At close: Jun 24, 2024, 9:31 AM
0.320
+0.006 (1.91%)
After-hours: Jun 24, 2024, 5:10 PM EDT
-0.73%
Market Cap 1.87M
Revenue (ttm) n/a
Net Income (ttm) -6.36M
Shares Out 6.01M
EPS (ttm) -2.40
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 46,995
Open 0.321
Previous Close 0.316
Day's Range 0.309 - 0.326
52-Week Range 0.260 - 5.470
Beta 0.80
Analysts Strong Buy
Price Target 4.00 (+1,173.89%)
Earnings Date Aug 7, 2024

About GLMD

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, a first-in-class synthetic fatty acid-bile acid conjugate molecule which is in Phase III study for oral treatment for non-alcoholic steato-hepatitis (NASH) in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Mar 13, 2014
Employees 3
Stock Exchange NASDAQ
Ticker Symbol GLMD
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for GLMD stock is "Strong Buy" and the 12-month stock price forecast is $4.0.

Price Target
$4.0
(1,173.89% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023

TEL AVIV, Israel , April 4, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic di...

2 months ago - PRNewsWire

Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis

TEL AVIV, Israel , March 15, 2024 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic d...

3 months ago - PRNewsWire

Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study

TEL AVIV, Israel , Nov. 20, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic di...

7 months ago - PRNewsWire

Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis

TEL AVIV, Israel , Sept. 26, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd.

9 months ago - PRNewsWire

Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification

TEL AVIV, Israel , Sept. 22, 2023 /PRNewswire/ —Galmed Pharmaceuticals Ltd.

9 months ago - PRNewsWire

Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering

TEL AVIV, Israel , July 14, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic di...

1 year ago - PRNewsWire

Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC

OnKai's AI models redefine the methodologies and economics of clinical trials TEL AVIV, Israel , July 10, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a...

1 year ago - PRNewsWire

Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments

TEL AVIV, Israel , June 1, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver and fibro-inflammatory dise...

1 year ago - PRNewsWire

Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC)

The clinical research and development program will be conducted in collaboration with the Stravitz–Sanyal Institute for Liver Disease and Metabolic Health Virginia Commonwealth University.    TEL AVIV...

1 year ago - PRNewsWire

Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022

TEL AVIV, Israel , March 29, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammato...

1 year ago - PRNewsWire

Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt

Expands foundational patent protection for Galmed's innovative first-in- class drug Aramchol through the end of 2034 This patent provides protection for Aramchol per se, not limited to any therapeutic...

1 year ago - PRNewsWire

Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

TEL AVIV, Israel , Dec. 14, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a biopharmaceutical company focused on the development of Aramchol and Amilo-5M...

1 year ago - PRNewsWire

Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results

TEL AVIV, Israel , Aug. 4, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramcho...

2 years ago - PRNewsWire

Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model

Statistically significant clinical and histology improvements were also demonstrated in a model of inflammatory bowel disease (IBD) Data reinforcing the expansion of Aramchol's Clinical Development to...

2 years ago - PRNewsWire

Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results

TEL AVIV, Israel , May 17, 2022 /PRNewswire/ —Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic, fibrosis and infl...

2 years ago - PRNewsWire

Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects

Recent data reinforce the anti-fibrotic activity of Aramchol previously observed in a wide range of pre-clinical models, in addition to the known effects in liver fibrosis The Open-Label Part of the A...

2 years ago - PRNewsWire

Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results

- Conference Call and Webcast Today at 8:30 a.m. ET / 5:30 a.m.

2 years ago - PRNewsWire

Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment

- Treatment with Aramchol 300mg BID resulted in a high rate of subjects with fibrosis improvement using NASH CRN, paired ranked reading and Artificial Intelligence (AI) quantitative digital analysis. ...

2 years ago - PRNewsWire

Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2

TEL AVIV, Israel, April 26, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of Aramch...

2 years ago - PRNewsWire

Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt

TEL AVIV, Israel, Jan. 11, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ-CM: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammat...

2 years ago - PRNewsWire

Galmed's Potential Ulcerative Colitis Candidate Shows Encouraging Action In Early Study

Galmed Pharmaceuticals Ltd (NASDAQ: GLMD) posted results of the Phase 1 trial of Amilo-5MER in healthy volunteers. Amilo-5MER is a synthetic peptide consisting of 5 amino acids that significantly redu...

2 years ago - Benzinga

Galmed announces positive results of Phase 1 study of Amilo-5MER

TEL AVIV, Israel, Jan. 10, 2022 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory...

2 years ago - PRNewsWire

Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results

TEL AVIV, Israel, Nov. 8, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of the live...

2 years ago - PRNewsWire

Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement

-- Updated liver histology data from first 20 patients show 60% fibrosis improvement by at least 1 stage as early as 24 weeks, data will be presented at AASLD Late Breaker Presentations -- -- Statisti...

2 years ago - PRNewsWire

Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study

TEL AVIV, Israel, Nov. 1, 2021 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD) ("Galmed" or the "Company"), a clinical-stage biopharmaceutical company for liver, metabolic and inflammatory ...

2 years ago - PRNewsWire